Acquired haemophilia: Diagnosis and therapeutic management;L'hémophilie acquise: Approches diagnostiques et thérapeutiques actuelles

Revue de Medecine Interne

Volumn 22, Issue 9, 2001, Pages 854-866

  Levesque H ^a   Borg, J Y ^b   Bossi, P ^c   Goudemand, J ^d   Guillet, B ^e   Cabane, J ^c  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e BICÊTRE HOSPITAL   (France)

Author keywords

Acquired haemophilia; Anti FVIIIc inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; CYCLOPHOSPHAMIDE; DESMOPRESSIN; IMMUNOGLOBULIN; OCTIM; PREDNISONE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VINCRISTINE;

ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; HEMOPHILIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MORTALITY; PLASMAPHERESIS; PREGNANCY; REMISSION; TREATMENT OUTCOME;

EID: 0034808836     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(01)00436-2     Document Type: Short Survey

References (92)

1. Hemorrhagic diathesis with prolonged coagulation time associated with a circulating anticoagulant
2. A survey of 215 non-hemophilic patients with inhibitors to factor VIII
3. Use of porcine factor VIII in the treatment of patients with acquired hemophilia
4. Acquired haemophilia
5. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy
6. Circulating anti-coagulants: A study of 40 cases and review of the literature
7. Acquired inhibitors to the blood coagulation factors
8. Acquired hemophilia due to factor VIII inhibitors in 34 patients
9. Acute abdominal pain due to an acquired disorder of coagulation
10. Corticosteroid therapy for acquired factor VIII: C inhibitors
11. Combinaison immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor
12. Hemorrhagic syndrome associated with a factor VIII: C inhibitor in a patient with lymphoma
13. Inhibiteur acquis du facteur VIII et leucémie lymphoïde chronique: À propos d'un cas
14. Does Sjögren's syndrome predispose surgical patients to acquired haemophilia?
15. Acquired factor VIII: C inhibitor in a patient with Sjgren's syndrome: Successful treatment with steroid and immunosuppressive therapy
16. Acquired haemophilia in a patient with myeloma
17. Cyclosporin therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus
18. Acquired haemophilia and rheumatoid arthritis
19. Acquired haemophilia and rheumatoid arthritis: Success of immunoglobulin therapy
20. Hémophilie acquise par autoanticorps anti-facteur VIII: Données cliniques, biologiques et indications thérapeutiques
21. Acquired haemophilia: A rare complication of Sjgren's syndrome
22. Acquired haemophilia: A study of ten cases
23. Pemphigus vulgaris associated with acquired haemophilia A due to factor VIII inhibitor
24. Acquired haemophilia, meningioma and diphenylhydantoin therapy
25. Acquired haemophilia: An important but often unrecognised cause of bleeding in elderly people
26. A hemorrhagic syndrome in Waldenstrom's macro-globulinemia secondary to immunoadsorption of factor VIII
27. Acquired inhibitor to human factor VIII associated with paraproteinemia and subsequent development of chronic lymphatic leukaemia
28. Acquired factor FVIII inhibitor preceding chronic lymphocytic leukemia
29. Acquired factor VIII inhibitor in a patient with malignant lymphoma
30. Acquired hemophilia in patients with hematologic malignancies
31. Acquired inhibitors in malignant and nonmalignant disease states
32. Spontaneously acquired anti-factor VIII antibodies: Report of a case with adenocarcinoma of the prostate
33. An acquired haemorrhagic disease in a female due to an inhibitor of blood coagulation
34. Postpartum lymphocytic thyroiditis: Prevalence, clinical course, and long-term follow-up
35. Factor VIII inhibitor postpartum
36. Autoanticorps acquis anti-facteur VIII humain. Une nouvelle observation
37. Acquired haemophilia A in women post partum: Management of bleeding episodes and natural history of the factor VIII antibodies
38. Post partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment
39. Acquired hemophilia A in women postpartum: Clinical manifestations, diagnosis and treatment
40. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting
41. Immunochemistry of factor VIII: C inhibitor antibodies
42. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation
43. A more uniform measurement of factor VIII inhibitors
44. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A. A French multicentric study
45. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption
46. Recommendations for the treatment of factor VIII inhibitors: From the UK Haemophilia Centre Directors Organisation Inhibitor Working Party
47. Rationale and evolution of therapy with porcine factor VIII: C
48. Auto-anticorps acquis contre le facteur VIII humain: Traitement de deux accidents hémorragiques par le facteur VIIIc porcin
49. The use of porcine factor VIII concentrate (Hyate: C) in the treatment of patients with inhibitor antibodies to VIII: C: A multicenter US trial
50. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies
51. Adverse effects of treatment with porcine factor VIII
52. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: The results of an international survey
53. Acquired haemophilia and its management
54. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors
55. Activated prothrombin concentrate for patients with factor VIII inhibitors
56. Efficacy of prothrombin complex concentrates in haemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial
57. The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII: A double-blind clinical trial
58. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor
59. Use of prothrombin complex concentrates in the management of bleeding in hemophiliacs with inhibitors: Benefits and limitations
60. Le facteur VII recombinant activé: Un nouveau traitement de l'hémophilie
61. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa
62. Factor VIIa in the treatment of haemophilia
63. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders
64. Safety and initial efficacy of three dose-levels of recombinant activated factor VII (rVIIa): Results of a phase I study
65. Prospective randomised trial of two doses of rFVIIa (Novosen) in haemophilia patients with inhibitors undergoing surgery
66. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors; the advantage of early intervention
67. Feasibility of using recombinant factor VIIa in continuous infusion
68. Desmopressin: A nontransfusional form of treatment of congenital and acquired bleeding disorders
69. Case report: Successful use of antifibrinolytic therapy in a non-hemophilic patient with acquired factor VIII inhibitor
70. The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) in a non-haemophilic patient with acquired type II factor VIII inhibitor
71. DDAVP in acquired haemophilia A: Case report and review of the literature
72. Antiidiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin
73. Recovery from anti-VIII: C autoimmune disease is dependent on generation of antiidiotypes against anti VIII: C autoantibodies
74. Failure of high-dose IV gamma globulin in the treatment of spontaneously acquired factor VIII inhibitors
75. An acquired factor VIII inhibitor responsive to high-dose gammaglobulin
76. Successful treatment with high-dose intravenous immunoglobulin in a patient with spontaneous inhibitor to factor VIII
77. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus
78. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin
79. Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor
80. Plasma exchange in non-haemophiliac patients with inhibitors to factor VIII: C
81. Plasmapheresis and factor VIII: C inhibitors
82. Successful treatment of a non-haemophilic patient with inhibitor to factor VIII by double-filtration plasmapheresis
83. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption
84. Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: A review of US clinical studies 1987-1990
85. Reduction of acquired high titer factor VIII antibodies by extracorporeal antibody-based immunoadsorption without additional immunosuppressive therapy
86. Corticosteroid therapy for acquired factor VIII: C inhibitors
87. A prospective randomised trial of prednisolone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies
88. Successful treatment of acquired hemophilia with oral immunosuppressive therapy
89. Combinaison immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor
90. Cyclosporine treatment of a woman with acquired haemophilia due to FVIII: C inhibitor
91. Postpartum factor VIII inhibitors: Report of two cases with special reference to the efficacy of various treatments
92. L'hémophilie acquise par autoanticorps anti-VIII: Modèle d'auto-imunité